2023
Therapeutic efficacy of intravenous infusion of mesenchymal stem cells in rat perinatal brain injury
Terada K, Sasaki M, Nagahama H, Kataoka-Sasaki Y, Oka S, Ukai R, Yokoyama T, Iizuka Y, Sakai T, Fukumura S, Tsugawa T, Kocsis J, Honmou O. Therapeutic efficacy of intravenous infusion of mesenchymal stem cells in rat perinatal brain injury. Pediatric Research 2023, 94: 1921-1928. PMID: 37422495, DOI: 10.1038/s41390-023-02717-9.Peer-Reviewed Original ResearchConceptsPerinatal brain injuryBrain injuryMesenchymal stem cellsIntravenous infusionVehicle groupBrain volumeTherapeutic efficacyInfused mesenchymal stem cellsLeft common carotid arteryHistological analysisNon-ischemic hemispherePostnatal day 7Common carotid arteryEmbryonic day 18Stem cellsHypoxia-ischemiaMSC infusionPreterm infantsGABAergic cellsNeurological functionSignificant complicationsCortical synapsesFunctional improvementCarotid arteryIntravenous administration
2022
The Impact of Purple-Flesh Potato (Solanum tuberosum L.) cv. “Shadow Queen” on Minor Health Complaints in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Maeda-Yamamoto M, Honmou O, Sasaki M, Haseda A, Kagami-Katsuyama H, Shoji T, Namioka A, Namioka T, Magota H, Oka S, Kataoka-Sasaki Y, Ukai R, Takemura M, Nishihira J. The Impact of Purple-Flesh Potato (Solanum tuberosum L.) cv. “Shadow Queen” on Minor Health Complaints in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients 2022, 14: 2446. PMID: 35745176, PMCID: PMC9227939, DOI: 10.3390/nu14122446.Peer-Reviewed Original ResearchConceptsMinor health complaintsHealth complaintsHealthy adultsMesenchymal stem cellsMSC countPlacebo groupWeeks 0Psychological stress responsesHealthy subjectsIntake periodStress responseAdverse effectsComplaintsTest groupStem cellsStudy determinesAdultsGroupCountPurple potatoesResponsePlaceboIrritabilityIntakeIngestionPharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study
Nakazaki M, Oka S, Magota H, Kiyose R, Onodera R, Ukai R, Kataoka-Sasaki Y, Sasaki M, Honmou O. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106520. PMID: 35523052, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106520.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPlatelet aggregation testCardioembolic strokePlatelet aggregationFXa inhibitorsOral anticoagulantsStroke patientsPharmacological differencesAdenosine diphosphateAggregation testConcurrent antiplatelet therapyIschemic stroke patientsCardioembolic stroke patientsOnset of symptomsResults Six patientsLight transmission aggregometryFactor Xa inhibitorsAntiplatelet therapySecondary preventionSix patientsAntiplatelet drugsAtrial fibrillationAntiplatelet effectXa inhibitorsDabigatran
2021
Intravenous Infusion of Mesenchymal Stem Cells Promotes the Survival of Random Pattern Flaps in Rats
Nakagawa T, Sasaki M, Kataoka-Sasaki Y, Yotsuyanagi T, Radtke C, Kocsis JD, Honmou O. Intravenous Infusion of Mesenchymal Stem Cells Promotes the Survival of Random Pattern Flaps in Rats. Plastic & Reconstructive Surgery 2021, 148: 799-807. PMID: 34550936, DOI: 10.1097/prs.0000000000008327.Peer-Reviewed Original ResearchConceptsMesenchymal stem cell groupStem cell groupIntravenous infusionRandom pattern flapsCell groupsMesenchymal stem cellsFlap survivalHistologic analysisRandom-pattern skin flapsBlood perfusionSurgical reconstruction optionsHigh expressionSkin flap survivalFibroblast growth factor-2 (FGF-2) mRNAQuantitative reverse transcription polymerase chain reactionStem cellsFlap survival areaReverse transcription-polymerase chain reactionSkin flap surgeryExperimental disease modelsSkin blood perfusionSkin flap modelSoft tissue defectsMasson's trichrome stainingMasson's trichrome staining resultsIntravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series
Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, Kato J, Sasaki Y, Ishiai S, Ito YM, Namioka A, Namioka T, Nakazaki M, Kataoka-Sasaki Y, Onodera R, Oka S, Sasaki M, Waxman SG, Kocsis JD. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clinical Neurology And Neurosurgery 2021, 203: 106565. PMID: 33667953, DOI: 10.1016/j.clineuro.2021.106565.Peer-Reviewed Original ResearchConceptsSpinal cord injuryAmerican Spinal Injury Association Impairment ScaleMSC infusionAutologous mesenchymal stem cellsASIA CASIA DIntravenous infusionMesenchymal stem cellsSCI patientsFunctional statusFunctional improvementSpinal cord injury patientsSpinal Cord Independence MeasureASIA B patientsASIA C patientsPhase 2 studySerious adverse eventsCord injury patientsCurrent therapeutic optionsStem cellsASIA BASIA gradeC patientsNeurologic improvementAdverse eventsFocal brainstem infarction in the adult rat
Namioka A, Namioka T, Sasaki M, Kocsis JD, Honmou O. Focal brainstem infarction in the adult rat. Lab Animal 2021, 50: 97-107. PMID: 33564191, DOI: 10.1038/s41684-021-00722-1.Peer-Reviewed Original ResearchConceptsBrainstem ischemiaNew therapeutic approachesIschemic lesionsFunctional recoveryTherapeutic approachesAnimal modelsFemale Sprague-Dawley ratsBrainstem ischemic lesionsLower basilar arteryArtery occlusion modelIschemic lesion volumeType of strokeReliable animal modelSprague-Dawley ratsBrainstem infarctionExtended observation periodNeurological deficitsBasilar arteryLesion volumeOcclusion modelAdult ratsIschemiaPresent symptomsSurvival rateHigher survival ratePostoperative spinal cord ischaemia: magnetic resonance imaging and clinical features
Yasuda N, Kuroda Y, Ito T, Sasaki M, Oka S, Ukai R, Nakanishi K, Mikami T, Shibata T, Harada R, Naraoka S, Kamada T, Kawaharada N. Postoperative spinal cord ischaemia: magnetic resonance imaging and clinical features. European Journal Of Cardio-Thoracic Surgery 2021, 60: 164-174. PMID: 33517384, DOI: 10.1093/ejcts/ezaa476.Peer-Reviewed Original ResearchConceptsIschemic spinal cord injurySpinal cord injuryMagnetic resonance imagingSpinal cord levelArtery territoryAortic surgeryAortic eventsCord levelCardiovascular surgeryAnterior spinal artery territoryPosterior spinal artery territoryResonance imagingThoracic spinal cord levelLumbar spinal cord levelsSpinal cord infarctionT2-weighted MRI scansSite of infarctionT2-weighted magnetic resonance imagesHigh-intensity areaCord infarctionInfarction patternArterial territoriesSerious complicationsClinical featuresCord injury
2020
“Chronic” State in Neural Diseases as the Target of Cellular Therapy with Mesenchymal Stem Cells
Sasaki M, Oka S, Kataoka-Sasaki Y, Kocsis JD, Honmou O. “Chronic” State in Neural Diseases as the Target of Cellular Therapy with Mesenchymal Stem Cells. World Neurosurgery 2020, 135: 375-376. PMID: 32143241, DOI: 10.1016/j.wneu.2019.12.137.Peer-Reviewed Original Research
2018
8.前臨床MRI を用いた脳梗塞に対する再生治療メカニズムの評価
Nagahama H, Suzuki J, Sasaki M, Nakazaki M, Honmou O. 8.前臨床MRI を用いた脳梗塞に対する再生治療メカニズムの評価. Japanese Journal Of Radiological Technology 2018, 74: 722-725. PMID: 30033967, DOI: 10.6009/jjrt.2018_jsrt_74.7.722.Peer-Reviewed Original ResearchActin, alpha, cardiac muscle 1 (ACTC1) knockdown inhibits the migration of glioblastoma cells in vitro
Wanibuchi M, Ohtaki S, Ookawa S, Kataoka-Sasaki Y, Sasaki M, Oka S, Kimura Y, Akiyama Y, Mikami T, Mikuni N, Kocsis JD, Honmou O. Actin, alpha, cardiac muscle 1 (ACTC1) knockdown inhibits the migration of glioblastoma cells in vitro. Journal Of The Neurological Sciences 2018, 392: 117-121. PMID: 30055382, DOI: 10.1016/j.jns.2018.07.013.Peer-Reviewed Original ResearchAccelerating Cell Therapy for Stroke in Japan
Houkin K, Shichinohe H, Abe K, Arato T, Dezawa M, Honmou O, Horie N, Katayama Y, Kudo K, Kuroda S, Matsuyama T, Miyai I, Nagata I, Niizuma K, Sakushima K, Sasaki M, Sato N, Sawanobori K, Suda S, Taguchi A, Tominaga T, Yamamoto H, Yamashita T, Yoshimine T. Accelerating Cell Therapy for Stroke in Japan. Stroke 2018, 49: e145-e152. PMID: 29581346, DOI: 10.1161/strokeaha.117.019216.Peer-Reviewed Original ResearchDigital Polymerase Chain Reaction Quantification of SERPINA1 Predicts Prognosis in High-Grade Glioma
Ookawa S, Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Ohtaki S, Noshiro S, Komatsu K, Akiyama Y, Mikami T, Mikuni N, Kocsis JD, Honmou O. Digital Polymerase Chain Reaction Quantification of SERPINA1 Predicts Prognosis in High-Grade Glioma. World Neurosurgery 2018, 111: e783-e789. PMID: 29309973, DOI: 10.1016/j.wneu.2017.12.166.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasExpression of SERPINA1Polymerase chain reactionDigital polymerase chain reactionExpression groupMedian overall survivalAnti-inflammatory roleHigh expression groupMessenger RNA expressionCell linesGlioblastoma multiforme cell linesHuman glioblastoma cell linesParaffin-embedded tissuesPredict PrognosisOverall survivalPoor prognosisGrade IIIPolymerase chain reaction quantificationSERPINA1 expressionSurgical samplesGrade IVImmunohistochemical analysisGlioblastoma cell linesGlioma tissuesPrognosis
2017
Cerebral aneurysm neck diameter is an independent predictor of progressive occlusion after stent-assisted coiling
Nakazaki M, Nonaka T, Nomura T, Onda T, Yonemasu Y, Takahashi A, Hashimoto Y, Honda O, Oka S, Sasaki M, Daibo M, Honmou O. Cerebral aneurysm neck diameter is an independent predictor of progressive occlusion after stent-assisted coiling. Acta Neurochirurgica 2017, 159: 1313-1319. PMID: 28488070, DOI: 10.1007/s00701-017-3199-8.Peer-Reviewed Original ResearchConceptsStent-assisted coilingProgressive occlusionIndependent predictorsOcclusion gradeNeck diameterNeuroform stentsMultivariate logistic regression analysisMultivariate logistic regression modelCurve analysisAneurysm neck diameterMean volume embolization ratioLogistic regression analysisCharacteristic curve analysisROC curve analysisLogistic regression modelsMedian neck diameterResidual aneurysmUnivariate analysisOdds ratioVolume embolization ratioAneurysmsCerebral aneurysmsInterleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas.
Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Otsuka Y, Yamaguchi M, Ohnishi H, Ohtaki S, Noshiro S, Ookawa S, Mikami T, Mikuni N, Honmou O. Interleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas. Journal Of Neurosurgical Sciences 2017, 62: 239-244. PMID: 28079349, DOI: 10.23736/s0390-5616.16.03793-0.Peer-Reviewed Original ResearchConceptsHigh-grade astrocytomasInterleukin-13 receptor alpha 2Overall survivalMIB-1 indexReceptor alpha 2Median OSPoor prognosisPatient ageCox proportional hazards modelWorld Health Organization gradeMedian overall survivalMedian survival benefitAdvanced patient ageAlpha 2Real-time quantitative reverse transcription polymerase chain reactionLow expression groupQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionProportional hazards modelTranscription-polymerase chain reactionExpression levelsSubset of casesParaffin-embedded glioma samplesHazard ratioSurvival benefitCo-expression of tissue factor and IL-6 in immature endothelial cells of cerebral cavernous malformations
Noshiro S, Mikami T, Kataoka-Sasaki Y, Sasaki M, Ohnishi H, Ohtaki S, Wanibuchi M, Mikuni N, Kocsis JD, Honmou O. Co-expression of tissue factor and IL-6 in immature endothelial cells of cerebral cavernous malformations. Journal Of Clinical Neuroscience 2017, 37: 83-90. PMID: 28087183, DOI: 10.1016/j.jocn.2016.12.023.Peer-Reviewed Original ResearchConceptsCerebral cavernous malformationsInterleukin-6Immature endothelial cellsTissue factorMRNA expression levelsEndothelial cellsCavernous malformationsSporadic cerebral cavernous malformationDistribution of TFExpression levelsNormal endothelial cellsClinical factorsPrognostic rolePathological findingsUnderlying pathologyOperative specimensMRNA expressionAssociation of TFAbnormal clustersMalformationsProgressive eventsMessenger RNACellsExpressionAssociation
2016
Biological relevance of tissue factor and IL-6 in arteriovenous malformations
Noshiro S, Mikami T, Kataoka-Sasaki Y, Sasaki M, Hashi K, Ohtaki S, Wanibuchi M, Mikuni N, Kocsis JD, Honmou O. Biological relevance of tissue factor and IL-6 in arteriovenous malformations. Neurosurgical Review 2016, 40: 359-367. PMID: 27542852, DOI: 10.1007/s10143-016-0780-1.Peer-Reviewed Original ResearchConceptsInterleukin-6Vascular endothelial growth factor receptor 2Arteriovenous malformationsTissue factorControl tissuesMRNA expressionEndothelial cellsAbnormal endothelial cellsPlatelet-derived growth factor receptor betaGrowth factor receptor 2Growth factor receptor betaEndothelial growth factor receptor 2Factor receptor 2Distribution of TFSporadic arteriovenous malformationsNormal endothelial cellsMessenger RNAAsymptomatic groupSymptomatic groupClinical factorsPrognostic rolePathological findingsShunt bloodUnderlying pathologyOperative specimensDouble balloon protection during carotid artery stenting for vulnerable carotid stenosis reduces the incidence of new brain lesions
Nakazaki M, Nonaka T, Takahashi A, Yonemasu Y, Nomura T, Onda T, Honda O, Hashimoto Y, Ohnishi H, Sasaki M, Daibo M, Honmou O. Double balloon protection during carotid artery stenting for vulnerable carotid stenosis reduces the incidence of new brain lesions. Acta Neurochirurgica 2016, 158: 1377-1386. PMID: 27138330, DOI: 10.1007/s00701-016-2816-2.Peer-Reviewed Original ResearchConceptsDouble balloon protectionCarotid artery stentingDistal balloon protectionDistal filter protectionBalloon protectionCarotid stenosisNew lesionsFilter protectionDistal protectionDiffusion-weighted imaging studiesNew brain lesionsProximal balloon occlusionResultsSixty-four patientsIndependent significant factorsPosterior cervical musclesLogistic regression analysisT1-weighted imagesIschemic complicationsEmbolic complicationsArtery stentingBalloon occlusionCervical musclesDWI findingsTarget lesionsOdds ratioACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S, Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Noshiro S, Akiyama Y, Mikami T, Mikuni N, Kocsis JD, Honmou O. ACTC1 as an invasion and prognosis marker in glioma. Journal Of Neurosurgery 2016, 126: 467-475. PMID: 27081897, DOI: 10.3171/2016.1.jns152075.Peer-Reviewed Original ResearchConceptsMedian overall survivalKarnofsky Performance Scale statusTime of diagnosisMIB-1 indexGBM patientsHazard ratioPatient ageRadiological findingsKaplan-Meier methodHigh-grade gliomasReal-time polymerase chain reactionQuantitative real-time polymerase chain reactionRemote recurrenceDistant recurrenceOverall survivalClinical featuresIndependent prognosticRecurrence rateWHO criteriaGrade IIIPolymerase chain reactionSurgical removalContralateral cerebralGrade IGrade II
2015
[Treatment of cerebral ischemia using mesenchymal stem cell-clinical trial phase III].
Nakazaki M, Oka S, Sasaki M, Honmou O. [Treatment of cerebral ischemia using mesenchymal stem cell-clinical trial phase III]. Nippon Jibiinkoka Gakkai Kaiho 2015, 118: 93. PMID: 26495511, DOI: 10.3950/jibiinkoka.118.93.Peer-Reviewed Original Research
2014
Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats
Suzuki S, Kawamata J, Iwahara N, Matsumura A, Hisahara S, Matsushita T, Sasaki M, Honmou O, Shimohama S. Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats. Neuroscience Letters 2014, 584: 276-281. PMID: 25449872, DOI: 10.1016/j.neulet.2014.10.039.Peer-Reviewed Original ResearchConceptsHuman bone marrow-derived mesenchymal stem cellsTherapeutic effectParkinson's diseaseCalcium binding adaptor molecule 1Mesenchymal stem cell administrationSubstantia nigra pars compactaHemi-parkinsonian rat modelParkinsonian model ratsTH-positive neuronsAdaptor molecule 1Anti-inflammatory factorsStem cell administrationNovel therapeutic optionsSham-operated ratsBone marrow-derived mesenchymal stem cellsMarrow-derived mesenchymal stem cellsGlial activationPars compactaCell administrationTherapeutic optionsDopaminergic neuronsModel ratsDopaminergic neurodegenerationNovel therapiesRat model